Venice Archer

6.1k total citations · 4 hit papers
16 papers, 4.6k citations indexed

About

Venice Archer is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Venice Archer has authored 16 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Venice Archer's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (7 papers) and Colorectal Cancer Treatments and Studies (5 papers). Venice Archer is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (7 papers) and Colorectal Cancer Treatments and Studies (5 papers). Venice Archer collaborates with scholars based in United Kingdom, Switzerland and Germany. Venice Archer's co-authors include Joachim von Pawel, Martin Reck, Alex Y. Chang, E.H. Tan, Kristine Pemberton, Tudor–Eliade Ciuleanu, Kevin Carroll, Sumitra Thongprasert, José Rodrigues Pereira and Nick Thatcher and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Venice Archer

16 papers receiving 4.5k citations

Hit Papers

Gefitinib plus best supportive care in previously treated... 2005 2026 2012 2019 2005 2009 2019 2010 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
    2005 1.7k citations Nick Thatcher, Alex Y. Chang et al. The Lancet profile →
  2. Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
    2009 1.2k citations Martin Reck, Joachim von Pawel et al. Journal of Clinical Oncology profile →
  3. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
    2019 1.1k citations Howard West, Michael McCleod et al. The Lancet Oncology profile →
  4. Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
    2010 498 citations Martin Reck, Joachim von Pawel et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Venice Archer United Kingdom 9 3.6k 3.6k 919 663 276 16 4.6k
Aleksandra Szczęsna Poland 23 4.2k 1.2× 4.4k 1.2× 1.2k 1.3× 665 1.0× 381 1.4× 73 5.8k
Hong‐Hong Yan China 31 2.8k 0.8× 2.5k 0.7× 870 0.9× 866 1.3× 223 0.8× 133 3.7k
Jin‐Ji Yang China 36 3.9k 1.1× 3.5k 1.0× 1.2k 1.3× 1.1k 1.6× 306 1.1× 146 4.9k
Bilal Piperdi United States 35 2.8k 0.8× 3.9k 1.1× 821 0.9× 518 0.8× 493 1.8× 119 5.0k
Dariusz M. Kowalski Poland 29 2.5k 0.7× 2.5k 0.7× 744 0.8× 525 0.8× 315 1.1× 173 3.8k
Davey B. Daniel United States 19 2.1k 0.6× 2.2k 0.6× 538 0.6× 688 1.0× 362 1.3× 82 3.3k
Andrew Weickhardt Australia 23 2.3k 0.7× 2.3k 0.6× 967 1.1× 527 0.8× 169 0.6× 111 3.4k
Shunichi Sugawara Japan 36 3.5k 1.0× 4.2k 1.2× 1.1k 1.2× 548 0.8× 448 1.6× 209 5.4k
Radj Gervais France 24 4.0k 1.1× 3.7k 1.0× 1.1k 1.1× 617 0.9× 162 0.6× 83 5.2k
Mircea Dediu Romania 19 5.1k 1.4× 4.8k 1.3× 1.6k 1.7× 894 1.3× 173 0.6× 55 6.6k

Countries citing papers authored by Venice Archer

Since Specialization
Citations

This map shows the geographic impact of Venice Archer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Venice Archer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Venice Archer more than expected).

Fields of papers citing papers by Venice Archer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Venice Archer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Venice Archer. The network helps show where Venice Archer may publish in the future.

Co-authorship network of co-authors of Venice Archer

This figure shows the co-authorship network connecting the top 25 collaborators of Venice Archer. A scholar is included among the top collaborators of Venice Archer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Venice Archer. Venice Archer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Zhang, Qing, W. Marston Linehan, Navdeep Pal, et al.. (2023). Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases. JTO Clinical and Research Reports. 4(4). 100483–100483. 7 indexed citations
2.
3.
Peters, Solange, Shirish M. Gadgeel, Tony Mok, et al.. (2022). Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST).. Journal of Clinical Oncology. 40(17_suppl). LBA9023–LBA9023. 4 indexed citations
4.
Kurzrock, Razelle, Amy R. MacKenzie, Adham Jurdi, et al.. (2021). Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK-positive (ALK+) solid tumors in a histology-agnostic setting.. Journal of Clinical Oncology. 39(15_suppl). TPS3155–TPS3155. 9 indexed citations
5.
Dziadziuszko, Rafał, Simonetta Mocci, David S. Shames, et al.. (2020). 1307P Blood-based genomic profiling of advanced non-small cell lung cancer (aNSCLC) patients (pts) from blood first assay screening trial (BFAST) and comparison with real-world data (RWD). Annals of Oncology. 31. S845–S846. 3 indexed citations
6.
West, Howard, Michael McCleod, Maen Hussein, et al.. (2019). Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 20(7). 924–937. 1137 indexed citations breakdown →
7.
8.
9.
Henschke, Claudia I., David F. Yankelevitz, Rowena Yip, et al.. (2016). Tumor volume measurement error using computed tomography imaging in a phase II clinical trial in lung cancer. Journal of Medical Imaging. 3(3). 35505–35505. 19 indexed citations
10.
Mok, Tony, В. А. Горбунова, Erzsébet Juhász, et al.. (2014). A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015). Journal of Thoracic Oncology. 9(6). 848–855. 39 indexed citations
11.
12.
Reck, Martin, В. А. Горбунова, Erzsébet Juhász, et al.. (2012). Tumour Biomarker and Plasma Time Course Data from Abigail, A Phase II Study of 1st-Line Bevacizumab + Chemotherapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC). Annals of Oncology. 23. ix405–ix405. 2 indexed citations
13.
14.
Reck, Martin, Joachim von Pawel, Petr Zatloukal, et al.. (2010). Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Annals of Oncology. 21(9). 1804–1809. 498 indexed citations breakdown →
15.
Reck, Martin, Joachim von Pawel, Petr Zatloukal, et al.. (2009). Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL. Journal of Clinical Oncology. 27(8). 1227–1234. 1174 indexed citations breakdown →
16.
Thatcher, Nick, Alex Y. Chang, Purvish M. Parikh, et al.. (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). The Lancet. 366(9496). 1527–1537. 1688 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aleksandra Szczęsna Breakdown of academic impact, for papers by Hong‐Hong Yan Breakdown of academic impact, for papers by Jin‐Ji Yang Breakdown of academic impact, for papers by Bilal Piperdi Breakdown of academic impact, for papers by Dariusz M. Kowalski Breakdown of academic impact, for papers by Davey B. Daniel Breakdown of academic impact, for papers by Andrew Weickhardt Breakdown of academic impact, for papers by Shunichi Sugawara Breakdown of academic impact, for papers by Radj Gervais Breakdown of academic impact, for papers by Mircea Dediu
Rankless by CCL
2026